Biogen Inc.（BIIB）资讯与事件BIIBBiogen Inc.

Stoke Therapeutics and Biogen Present Epilepsy Data in Athens

Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress September 5-9 in Athens. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The global, pivotal Phase 3 EMPEROR study is underway to evaluate the safety and efficacy of zorevunersen, and results are anticipated in 3Q27. Improvements in cognition and behavior were sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile. New exploratory sub-analyses show effects on the most severe seizure types, which are the leading risk factor for sudden unexpected death in epilepsy, as well as improvements in quality of life for patients treated with zorevunersen. Zorevunersen continues to be generally well tolerated, with some patients treated for more than 5 years in the Phase 1/2a and ongoing OLE studies. As of July 31, more than 930 doses have been administered.

Eisai and Biogen Receive Positive Recommendation for Leqembi from Canada's Drug Agency

Eisai (ESAIY) and Biogen Canada (BIIB) announced receipt of the Canada's Drug Agency' final positive recommendation supporting public reimbursement for Leqembi, for eligible Canadians living with mild cognitive impairment or mild dementia due to Alzheimer's disease. Leqembi is the first treatment approved in Canada that targets the underlying biology of Alzheimer's disease and may help keep patients in the earlier stages of disease for longer, the companies said in a statement.

Eisai and Biogen Launch Early Alzheimer's Treatment in the U.S.

Eisai (ESAIY) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection is now available in the U.S. for initiation therapy for early Alzheimer's disease in adults with mild cognitive impairment or mild dementia due to AD, collectively referred to as early AD.